I could respond.
As somebody who was involved in that process, I can say there was no specific triggering event. Our current drug regulation process is based on the experience that came out of thalidomide. The latest round looking at post-marketing surveillance is from Vioxx. There was no such triggering event for the common drug review. There was, I guess, just the experience of all of us doing exactly the same thing in trying to review the same medical literature for the same drug. The larger provinces had very rigorous, evidence-based, critical appraisal systems similar to the CDR. The smaller provinces didn't have that capacity, and so we were looking at ways to share that and to be able to improve the quality of the drug reviews in those provinces that didn't have the capacity.
But to answer your question directly, no, there was no precipitating event to lead us down this path.